The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.

The present invention provides a novel coronavirus duplex detection kit. Specifically, the present invention discloses a kit and method for multiplex detection of novel coronavirus 2019-nCoV nucleic acid, which can simultaneously detect two nucleic acid targets of the novel coronavirus 2019-nCoV and possess extremely high sensitivity and specificity, and significantly improve the accuracy of virus identification.

The present invention provides binding molecules, including monoclonal antibodies, multi-specific antibodies, and antibody fragments, that specifically bind to the coronavirus, such as SARS-CoV-2, and methods of use thereof. In some aspects of the invention, the binding molecules are human antibodies, fragments, or derivatives thereof that specifically bind to SARS-CoV-2 spike protein. In some aspects of the invention, the binding molecules function to neutralize SARS-CoV-2. The present invention also relates to methods of using the binding molecules and compositions for diagnosis and treatment.

The present disclosure provides methods for treating or preventing a viral infection with one or more arylamide compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same, and pharmaceutical compositions comprising one or more arylamide compounds and at least one antiviral agent.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.

The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.

The present disclosure provides methods for treating or preventing a viral infection with one or more arylamide compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same, and pharmaceutical compositions comprising one or more arylamide compounds and at least one antiviral agent.